Channel Therapeutics CORP Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
Ikarian Capital, LLC and Neil Shahrestani have reported a 7.7% beneficial ownership stake in Pelthos Therapeutics Inc. via a Schedule 13G filing.
Investment firm 3i, LP and affiliates report a 9.9% beneficial ownership stake in Pelthos Therapeutics Inc. via Schedule 13G amendment.
3i, LP, along with 3i Management LLC and Maier Joshua Tarlow, updated their beneficial ownership in Pelthos Therapeutics Inc. to 9.99% of common stock.
Ikarian Capital, LLC and Neil Shahrestani have reported a 6.1% passive beneficial ownership stake in Pelthos Therapeutics Inc., holding 186,408 shares of common stock.
Murchinson Ltd. and CEO Marc Bistricer have jointly reported a 9.1% beneficial ownership stake in Pelthos Therapeutics Inc., totaling 280,000 shares.
AME Equities LLC and Ruth Friedman have filed an amendment to their Schedule 13G, indicating they no longer beneficially own more than 5% of Pelthos Therapeutics Inc. common stock.
SCHEDULE: Investment Entities Disclose 9.9% Stake in Pelthos Therapeutics Following Reverse Stock Split
3i, LP, 3i Management LLC, and Maier Joshua Tarlow have disclosed a 9.9% beneficial ownership stake in Pelthos Therapeutics Inc., holding 303,138 shares of common stock after the company's 1-for-10 reverse stock split.
SCHEDULE 13G: Ikarian Capital and Neil Shahrestani Disclose 7.3% Passive Stake in Channel Therapeutics Corp
Ikarian Capital, LLC and Neil Shahrestani have jointly disclosed a passive 7.3% beneficial ownership stake in Channel Therapeutics Corp, totaling 440,849 shares of common stock.
Alexandra Wood (Canada) Inc. has reported a 9.53% beneficial ownership stake in Channel Therapeutics Corp, holding 574,187 shares of common stock.